Bernhard Mortl
Munich, BY, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
What can claims data tell us about risk factors and survival of patients with hepatocellular carcinoma? Insights from a German population-based study.
Journal: Frontiers in oncology
Published: June 20, 2025
Treatment gaps and survival outcomes of hepatocellular carcinoma: insights from a nationwide, claims-based study.
Journal: Therapeutic advances in medical oncology
Published: February 02, 2025
Follicular lymphoma or diffuse large B-cell lymphoma: a population based analysis of epidemiological and health economic aspects in Germany.
Journal: Annals of hematology
Published: July 30, 2024
Response to the letter re: Changing treatment landscape associated with improved survival in advanced hepatocellular carcinoma: A nationwide, population-based study.
Journal: European journal of cancer (Oxford, England : 1990)
Published: December 10, 2023
Changing treatment landscape associated with improved survival in advanced hepatocellular carcinoma: a nationwide, population-based study.
Journal: European journal of cancer (Oxford, England : 1990)
Published: April 14, 2023
Budget Impact Analysis of CAR T-cell Therapy for Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma in Germany.
Journal: HemaSphere
Published: December 06, 2021
Inpatient treatment of relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL): A health economic perspective.
Journal: Clinical lymphoma, myeloma & leukemia
Published: October 04, 2021
Showing 1-8 of 8
Last Updated: 09/26/2026